FcRn inhibitors: a novel option for the treatment of myasthenia gravis.

Although the primary endpoint (change in the QMG score from baseline to day 29) between the rozanolixizumab and placebo groups did not reach statistical significance, improvements were seen both in MG-ADL scores and the daily functioning of patients (Bril et al., 2021).

also in 111,027 other papers